IP Library Granted Patent US 12,209,267
Granted Patent B2
US 12,209,267 · App. 18/172,594 · Granted Jan 28, 2025

Microbial production of rotundone

Inventors: Ryan N. Philippe (Cambridge, MA); Ajikumar Parayil Kumaran (Cambridge, MA); Christine Nicole S. Santos (Cambridge, MA); Jason Donald (Cambridge, MA); Stephen Sarria (Cambridge, MA)
Assignee: Manus Bio Inc.
C12P7/26C12N9/0006C12N9/0071C12N9/1085C12N9/88C12N15/52C12Y205/0101C12Y402/03087
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,267
App. No.
18/172,594
Granted
Jan 28, 2025
Kind
B2
Abstract

The present disclosure provides methods and compositions for producing rotundone. In various aspects, the present disclosure provides enzymes, polynucleotides encoding said enzymes, and recombinant microbial host cells (or microbial host strains) for the production of rotundone. In some embodiments, the present disclosure provides microbial host cells for producing rotundone at high purity and/or yield, from either enzymatic transformation of α-guaiene, or from sugar or other carbon source. The present disclosure further provides methods of making products containing rotundone, including flavor or fragrance products, among others.

Claims (24)

1. A microbial host cell for producing rotundone, the microbial cell expressing a heterologous α-guaiene synthase enzyme (αGTPS) and a heterologous α-guaiene oxidase (αGOX) enzyme; wherein the αGOX enzyme comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 51 or SEQ ID NO: 52.

2. The microbial cell of claim 1 , wherein the microbial host cell expresses a cytochrome P450 reductase enzyme.

3. The microbial cell of claim 2 , wherein the cytochrome P450 reductase enzyme comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 53 or SEQ ID NO: 33.

4. The microbial cell of claim 1 , wherein the αGTPS and αGOX are expressed together in an operon.

5. The microbial cell of claim 1 , wherein the microbial host cell further expresses one or more alcohol dehydrogenases (ADHs).

6. The microbial cell of claim 5 , wherein the ADH comprises an amino acid sequence of any one of SEQ ID NOs: 35-44, or an amino acid sequence that is at least 90% identical thereto.

7. The microbial cell of claim 5 , wherein the ADH comprises an amino acid sequence having 90% or more sequence identity to SEQ ID NO: 43.

8. The microbial cell of claim 1 , wherein the microbial host cell overexpresses one or more enzymes in a methylerythritol phosphate (MEP) or a mevalonic acid (MVA) pathway.

9. The microbial cell of claim 1 , wherein the microbial cell is a bacteria, optionally selected from Escherichia spp., Bacillus spp., Corynebacterium spp., Rhodobacter spp., Zymomonas spp., Vibrio spp., and Pseudomonas spp.

10. The microbial cell of claim 9 , wherein the microbial cell is Escherichia coli.

11. The microbial cell of claim 1 , wherein the microbial host cell is a yeast, optionally selected from Saccharomyces, Pichia , or Yarrowia.

12. The microbial cell of claim 1 , wherein the αGOX enzyme comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 51.

13. The microbial cell of claim 1 , wherein the αGOX enzyme comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 51.

14. The microbial cell of claim 1 , wherein the αGOX enzyme comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 51.

15. The microbial cell of claim 1 , wherein the αGOX enzyme comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 52.

16. The microbial cell of claim 1 , wherein the αGOX enzyme comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 52.

17. The microbial cell of claim 1 , wherein the αGOX enzyme comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 52.

18. The microbial cell of claim 1 , wherein αGTPS enzyme comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from SEQ ID NOS: 1, 3, 4, 6-10, 11-15, and 19.

19. The microbial cell of claim 1 , wherein αGTPS enzyme comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 8.

20. A method for making rotundone, comprising: culturing the microbial cell of claim 1 , and recovering the rotundone.

21. The method of claim 20 , wherein the culturing is performed using a batch culture, continuous culture, or semi-continuous culture that has a volume of at least 100 L.

22. The method of claim 21 , wherein the culture has a volume of at least 1000 L.

23. The method of claim 20 , wherein the rotundone is recovered by partitioning into an organic phase, followed by fractional distillation.

24. The method of claim 20 , wherein the culturing is a batch culture.

Assignments (2)
SECURITY INTEREST Recorded Sep 8, 2025
From: MANUS BIO INC.; STO.PERU I LLC; STO.PERU II LLC; MANUS INTERMEDIATE INC.; MANUS INSCRIPTA, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 072836/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2024
From: PHILIPPE, RYAN N.; KUMARAN, AJIKUMAR PARAYIL; SANTOS, CHRISTINE NICOLE S.; DONALD, JASON; SARRIA, STEPHEN
To: MANUS BIO, INC.
Reel/Frame 069605/0522 →
Continuity (3)
Continuation 17273567
Provisional Application 62727815 · Sep 6, 2018
Related Publication 20230183760A1 · Jun 15, 2023
References Cited (32)
US 9404130B2 · Ajikumar et al. · 2016 [cited by applicant]
US 9796980B2 · Ajikumar et al. · 2017 [cited by applicant]
US 9957527B2 · Ajikumar et al. · 2018 [cited by applicant]
US 10463062B2 · Philippe et al. · 2019 [cited by applicant]
US 10480015B2 · Kumaran et al. · 2019 [cited by applicant]
US 10501760B2 · Kumaran et al. · 2019 [cited by applicant]
US 10662442B2 · Kumaran et al. · 2020 [cited by applicant]
US 10774314B2 · Donald et al. · 2020 [cited by applicant]
US 10934564B2 · Kumaran et al. · 2021 [cited by applicant]
US 20150007368A1 · Saran et al. · 2015 [cited by applicant]
US 20150218588A1 · Schalk et al. · 2015 [cited by applicant]
US 20170356059A1 · Kino et al. · 2017 [cited by applicant]
US 20180135081A1 · Kumaran et al. · 2018 [cited by applicant]
US 20200299737A1 · Goeke · 2020 [cited by examiner]
US 20210161092A1 · Kumaran et al. · 2021 [cited by applicant]
JP 2016154502A · 2016 [cited by examiner]
JP 2017525395A · 2017 [cited by applicant]
JP 2017216974A · 2017 [cited by applicant]
WO WO2016029153A1 · 2016 [cited by applicant]
EP patent application 17205361.3 filed Dec. 5, 2017. (Year: 2017). [cited by examiner]
Drew, et al., “Two key polymorphisms in a newly discovered allele of the [cited by applicant]
Kato, et al., “Enhanced Production of δ-Guaiene, a Bicyclic Sesquiterpene Accumulated in Agarwood, by Coexpression of δ-Guaiene Synthase and Farnesyl Diphosphate Synthase Genes in [cited by applicant]
Degenhardt, et al., “Monoterpene and sesquiterpene synthases and the origin of terpene skeletal diversity in plants,” Phytochemistry, 2009, vol. 70, Issues 15-16, pp. 1621-1637. [cited by applicant]
GenBank, Accession No. JF289265, 2011, www.ncbi.nlm.nih.gov. [cited by applicant]
GenBank, Accession No. AMQ67166, 2016, www.ncbi.nlm.gov. [cited by applicant]
GenBank, Accession No. XM 002282452, 2016, www.ncbi.nlm.nih.gov. [cited by applicant]
GenBank, Accession No. A0A076U535, 2018, www.ncbi.nlm.nih.gov. [cited by applicant]
Kumeta, et al., “Genomic organization of δ-guaiene synthase genes in [cited by applicant]
Uniprot, Accession No. Q46856, 2017, www.uniprot.org. [cited by applicant]
Extended European Search Report for EP 19856874.3, dated Apr. 26, 2022, 10 pgs. [cited by applicant]
Takase, et al., “Chtochrome P450 CYP71BE5 in grapevine ( [cited by applicant]
Drew, et al. ‘Two Key Polymorphisms in a Newly Discovered Allele of the [cited by applicant]